Core Viewpoint - The company, Four Seasons Pharmaceutical, has announced a strategic investment in Swiss aesthetic company Suisselle SA, marking a significant step in its global expansion strategy in the medical aesthetics industry [2] Group 1: Investment Details - Four Seasons Pharmaceutical will complete its investment in Suisselle SA by September 2025, having signed a subscription agreement [2] - The partnership grants Four Seasons exclusive agency rights for the CELLBOOSTER® product line, allowing deep involvement in its operations and development [2] Group 2: Company Background - Suisselle, established in 2010, is a leading manufacturer of water-light needle products, with its CELLBOOSTER® series utilizing patented CHAC technology [2] - The company has expanded its business to 43 countries, showcasing its international reach and market presence [2] Group 3: Strategic Implications - The collaboration will enable Four Seasons to leverage Suisselle's established platform in Europe to accelerate the promotion and sales of its self-developed medical aesthetic products in European and other overseas markets [2] - The partnership aims to continuously introduce innovative products from Suisselle and other European sources, enhancing the domestic medical aesthetic product portfolio [2] - This investment is described as a key step in Four Seasons' global strategy for its medical aesthetics sector [2]

Core Viewpoint - The company has signed an investment agreement to acquire a stake in Swiss aesthetic company Suisselle SA, enhancing its strategic relationship and expanding its presence in the global aesthetic market [1][2] Group 1: Investment Details - The investment in Suisselle will allow the company to permanently hold exclusive agency rights for the CELLBOOSTER product in China, strengthening long-term collaboration [1] - The partnership will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed aesthetic products in European and other overseas markets [1] Group 2: Strategic Expansion - The investment marks a significant step in the company's global strategy for the aesthetic business, completing its strategic layout in the core aesthetic markets of Europe and North America [2] - The company aims to continue driving high-quality aesthetic solutions through a combination of independent research and international collaboration, creating long-term sustainable value for shareholders and investors [2]

智通财经APP讯，四环医药(00460)发布公告，本集团于2025年9月对瑞士医美公司Suisselle SA(Suisselle) 进行投资入股，双方已正式签署投资认购协议。此次合作将提升本集团与Suisselle的战略关系，共同拓 展全球医美市场。 本集团早在2022年已获得CELLBOOSTER水光针在中国地区的独家代理权，本次投资入股将进一步强 化双方长期合作关系。通过本次投资入股，本集团将永久享有CELLBOOSTER水光针产品的独家代理 权益，并深度参与其运营与发展。 此外，本次四环医药投资入股Suisselle后，双方将合作通过Suisselle在欧洲的成熟平台，加速本集团旗 下"渼颜空间"自研医美产品在欧洲及其他海外市场的推广与销售。同时，本集团将持续引入Suisselle及 其他欧洲创新产品，丰富国内医美产品矩阵。这一布局与本集团全球化战略高度契合，旨在构建覆盖研 发、生产与销售的国际化医美生态体系。 近年来，本集团积极推进医美业务全球化战略，于2021年全资收购美国医疗美容器械公司Genesis Biosystems，成功切入北美市场。此次投资Suisselle，是本集团医美产业全球化战略 ...

Core Viewpoint - Jiangsu Wuzhong (ST Suwu) faces a significant setback as its subsidiary, Datou Medical, receives a termination notice from Regen Biotech, ending their exclusive distribution agreement for AestheFill in mainland China, which may lead to a loss of market position and revenue [2][11]. Group 1: Company Developments - Jiangsu Wuzhong's subsidiary, Datou Medical, had secured exclusive rights for AestheFill in August 2022, with expectations of significant revenue contributions [5][6]. - AestheFill was projected to generate substantial profits, contributing 3.26 billion yuan in sales and 2.69 billion yuan in gross profit for Jiangsu Wuzhong in 2024 [6]. - Following the termination notice, Jiangsu Wuzhong's stock plummeted by 5.03%, reducing its market capitalization to 1.211 billion yuan [3]. Group 2: Market Context - The aesthetic medicine market, particularly the "童颜针" (youthful needle) segment, is rapidly growing, with the market size approaching 600 million yuan in 2023 [16]. - Increased competition in the market is evident, with multiple products receiving approval, intensifying the struggle for market share [16]. - The loss of AestheFill's distribution rights could significantly impact Jiangsu Wuzhong's revenue and market strategy in the aesthetic sector [16]. Group 3: Legal and Strategic Responses - Jiangsu Wuzhong has initiated a response plan and is in active communication with Regen, considering legal action to protect its interests [11][13]. - The company has publicly condemned Regen's unilateral termination of the agreement, asserting that it violates the contractual spirit and could disrupt market order [11][13].

Core Viewpoint - Jiangsu Wuzhong (ST Suwu) faces significant challenges as its subsidiary, Datou Medical, loses exclusive distribution rights for AestheFill in mainland China due to a termination notice from Regen Biotech, which may lead to a substantial decline in revenue and profits for the company [1][6]. Company Summary - Jiangsu Wuzhong's subsidiary, Datou Medical, received a termination notice from Regen Biotech, ending its exclusive distribution agreement for AestheFill, a key product in the high-end medical aesthetics market [1][3]. - The exclusive distribution agreement was initially signed in August 2022, granting Datou Medical rights until August 2032, with Regen promising no legal obstacles to the agreement [3]. - AestheFill significantly contributed to Jiangsu Wuzhong's financial recovery, with projected sales of 10 million units in 2024 and a net profit of 70.48 million yuan, marking a 197.97% increase year-on-year [3][4]. - Following the termination notice, Jiangsu Wuzhong's stock fell to 1.7 yuan per share, a 5.03% drop, reducing its market capitalization to 1.211 billion yuan [2]. Industry Summary - The medical aesthetics industry, particularly the "童颜针" (youthful injection) market, is rapidly growing, with the market size approaching 600 million yuan in 2023 [7]. - The competitive landscape is intensifying, with multiple companies vying for market share, including the recent entry of new products and brands [7]. - The loss of AestheFill's distribution rights could significantly impact Jiangsu Wuzhong's position in the medical aesthetics sector, raising concerns about its future growth and market presence [7].